245 related articles for article (PubMed ID: 25100057)
1. Control of gluconeogenesis by metformin: does redox trump energy charge?
Baur JA; Birnbaum MJ
Cell Metab; 2014 Aug; 20(2):197-9. PubMed ID: 25100057
[TBL] [Abstract][Full Text] [Related]
2. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.
Madiraju AK; Erion DM; Rahimi Y; Zhang XM; Braddock DT; Albright RA; Prigaro BJ; Wood JL; Bhanot S; MacDonald MJ; Jurczak MJ; Camporez JP; Lee HY; Cline GW; Samuel VT; Kibbey RG; Shulman GI
Nature; 2014 Jun; 510(7506):542-6. PubMed ID: 24847880
[TBL] [Abstract][Full Text] [Related]
3. Metformin's Therapeutic Efficacy in the Treatment of Diabetes Does Not Involve Inhibition of Mitochondrial Glycerol Phosphate Dehydrogenase.
MacDonald MJ; Ansari IH; Longacre MJ; Stoker SW
Diabetes; 2021 Jul; 70(7):1575-1580. PubMed ID: 33849997
[TBL] [Abstract][Full Text] [Related]
4. Low metformin causes a more oxidized mitochondrial NADH/NAD redox state in hepatocytes and inhibits gluconeogenesis by a redox-independent mechanism.
Alshawi A; Agius L
J Biol Chem; 2019 Feb; 294(8):2839-2853. PubMed ID: 30591586
[TBL] [Abstract][Full Text] [Related]
5. The target of metformin in type 2 diabetes.
Ferrannini E
N Engl J Med; 2014 Oct; 371(16):1547-8. PubMed ID: 25317875
[No Abstract] [Full Text] [Related]
6. Molecular action of metformin in hepatocytes: an updated insight.
Sliwinska A; Drzewoski J
Curr Diabetes Rev; 2015; 11(3):175-81. PubMed ID: 25808533
[TBL] [Abstract][Full Text] [Related]
7. Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis.
LaMoia TE; Butrico GM; Kalpage HA; Goedeke L; Hubbard BT; Vatner DF; Gaspar RC; Zhang XM; Cline GW; Nakahara K; Woo S; Shimada A; Hüttemann M; Shulman GI
Proc Natl Acad Sci U S A; 2022 Mar; 119(10):e2122287119. PubMed ID: 35238637
[TBL] [Abstract][Full Text] [Related]
8. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo.
Madiraju AK; Qiu Y; Perry RJ; Rahimi Y; Zhang XM; Zhang D; Camporez JG; Cline GW; Butrico GM; Kemp BE; Casals G; Steinberg GR; Vatner DF; Petersen KF; Shulman GI
Nat Med; 2018 Sep; 24(9):1384-1394. PubMed ID: 30038219
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin.
Wollen N; Bailey CJ
Biochem Pharmacol; 1988 Nov; 37(22):4353-8. PubMed ID: 3058129
[TBL] [Abstract][Full Text] [Related]
10. Metformin lowers glucose 6-phosphate in hepatocytes by activation of glycolysis downstream of glucose phosphorylation.
Moonira T; Chachra SS; Ford BE; Marin S; Alshawi A; Adam-Primus NS; Arden C; Al-Oanzi ZH; Foretz M; Viollet B; Cascante M; Agius L
J Biol Chem; 2020 Mar; 295(10):3330-3346. PubMed ID: 31974165
[TBL] [Abstract][Full Text] [Related]
11. Current understanding of metformin effect on the control of hyperglycemia in diabetes.
An H; He L
J Endocrinol; 2016 Mar; 228(3):R97-106. PubMed ID: 26743209
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial GCN5L1 regulates cytosolic redox state and hepatic gluconeogenesis via glycerol phosphate shuttle GPD2.
Meng J; Zhang C; Wang D; Zhu L; Wang L
Biochem Biophys Res Commun; 2022 Sep; 621():1-7. PubMed ID: 35802941
[TBL] [Abstract][Full Text] [Related]
13. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.
Owen MR; Doran E; Halestrap AP
Biochem J; 2000 Jun; 348 Pt 3(Pt 3):607-14. PubMed ID: 10839993
[TBL] [Abstract][Full Text] [Related]
14. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.
Foretz M; Hébrard S; Leclerc J; Zarrinpashneh E; Soty M; Mithieux G; Sakamoto K; Andreelli F; Viollet B
J Clin Invest; 2010 Jul; 120(7):2355-69. PubMed ID: 20577053
[TBL] [Abstract][Full Text] [Related]
15. Thyroid hormone and dehydroepiandrosterone permit gluconeogenic hormone responses in hepatocytes.
Kneer N; Lardy H
Arch Biochem Biophys; 2000 Mar; 375(1):145-53. PubMed ID: 10683260
[TBL] [Abstract][Full Text] [Related]
16. Integrated or Independent Actions of Metformin in Target Tissues Underlying Its Current Use and New Possible Applications in the Endocrine and Metabolic Disorder Area.
Tulipano G
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884872
[TBL] [Abstract][Full Text] [Related]
17. Cellular and Molecular Mechanisms of Metformin Action.
LaMoia TE; Shulman GI
Endocr Rev; 2021 Jan; 42(1):77-96. PubMed ID: 32897388
[TBL] [Abstract][Full Text] [Related]
18. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.
Yoshida T; Okuno A; Tanaka J; Takahashi K; Nakashima R; Kanda S; Ogawa J; Hagisawa Y; Fujiwara T
Eur J Pharmacol; 2009 Nov; 623(1-3):141-7. PubMed ID: 19765581
[TBL] [Abstract][Full Text] [Related]
19. Acute renal metabolic effect of metformin assessed with hyperpolarised MRI in rats.
Qi H; Nielsen PM; Schroeder M; Bertelsen LB; Palm F; Laustsen C
Diabetologia; 2018 Feb; 61(2):445-454. PubMed ID: 28936623
[TBL] [Abstract][Full Text] [Related]
20. Organization and regulation of the cytosolic NADH metabolism in the yeast Saccharomyces cerevisiae.
Rigoulet M; Aguilaniu H; Avéret N; Bunoust O; Camougrand N; Grandier-Vazeille X; Larsson C; Pahlman IL; Manon S; Gustafsson L
Mol Cell Biochem; 2004; 256-257(1-2):73-81. PubMed ID: 14977171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
